29 results
Systemic Lupus Erythematosus - Summary
Antinuclear (ANA) - 95% - Initial screening test
Anti-dsDNA - 50%
 • Associated
Systemic Lupus Erythematosus ... Treatment: • ... #Lupus #Erythematosus ... Summary #diagnosis #rheumatology ... #management
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Systemic Lupus Erythematosus ... life-threatening • Treatment ... Evolution: Chronic disease ... #Systemic #Erythematosus ... #Summary #rheumatology
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
Manifestations of Systemic ... Cerebrovascular Disease ... Puncture, EEG Treatment ... cerebritis #diagnosis #management ... #treatment
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
• Systemic lupus ... lupus erythematosus ... Treatment: • Corticosteroids ... Syndrome #Diagnosis #Management ... #Hematology #Rheumatology
Behcet's Syndrome - Treatment
Ulcers:
 • Treatment: Topical steroids
 • Prevention: Colchicine
 • Azathioprine for refractory disease
Arthritis:
Behcet's Syndrome - Treatment ... Ulcers: • Treatment ... : • Systemic steroids ... #management #pharmacology ... #rheumatology
Adult-Onset Still's Disease
Clinical triad: Fever, Arthralgia/arthritis, Skin rash ± odynophagia
+ Biological inflammation: Increased neutrophils, Hyperferritinemia, decreased
Adult-Onset Still's Disease ... solid cancers • Systemic ... diseases : other ... #diagnosis #management ... #treatment #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
months to years) Systemic ... life-threatening • Treatment ... Usual therapeutic management ... Evolution: Chronic disease ... #diagnosis #management
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
mycobacterial infection (NTM ... Tuberculosis Treatment ... Initiating Treatment ... TB #Diagnosis #Management ... #Treatment #ActiveTB
Systemic Therapy for Hepatocellular Carcinoma - AGA Clinical Practice Guideline

First Line Treatment for HCC with Preserved
Systemic Therapy ... for Disease Progression ... Hepatocellular #Carcinoma #Systemic ... #Treatment #Management ... #Hepatology #Gastroenterology
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
mycobacterial infection (NTM ... Tuberculosis Treatment ... Initiating Treatment ... TB #Diagnosis #Management ... #Treatment #ActiveTB